Screener
ArriVent BioPharma, Inc. AVBP Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from ArriVent BioPharma, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026. Open the filing →
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
FAQ
- What is ArriVent BioPharma, Inc.'s debt-to-equity?
- ArriVent BioPharma, Inc. (AVBP) reported debt-to-equity of 0× in Q1 2026.
- How has ArriVent BioPharma, Inc.'s debt-to-equity changed year-over-year?
- ArriVent BioPharma, Inc.'s debt-to-equity increased by 85.7% year-over-year, from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about ArriVent BioPharma, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude